Inclusion Criteria

Inclusion criteria

- Subjects with a diagnosis of non-M3 AML, Relapsed or refractory ALL or Intermediate
Risk 2 or High Risk disease MDS as follows:

- Subjects with a diagnosis of non-M3 AML which meets one of the following criteria:

1. Ages 60 or older: Relapsed or refractory after at least one prior therapy for
AML

2. Ages 60 or older: Newly diagnosed in a patient with a preceding history of
myelodysplastic syndrome which has been treated with azacitidine or decitabine
and who are not appropriate candidates for aggressive therapy including
induction followed by allogeneic stem cell transplantation.

3. Ages 18-59: Relapsed or refractory disease after failing three prior lines of
therapy

- Subjects with a diagnosis of relapsed or refractory ALL: must have failed three prior
lines of therapy and be 18 years of age or older.

- Subjects with a diagnosis of Intermediate Risk 2 or High Risk disease (as defined by
IPSS score): must have failed to respond/intolerant to, or progressed after a
hypomethylating agent, and must not be candidates for allogeneic stem cell
transplantation.

2). Life expectancy of at least 4 weeks 3). Must have recovered from toxic effects of
prior chemotherapy 4). Patients must be able to sign consent and be willing and able
to comply with scheduled visits, treatment plan and laboratory testing.

Exclusion criteria

1. . Cytotoxic chemotherapy (including azacitadine or decitabine) within the past 28
days other than hydroxyurea

2. . Active participation in any other investigational treatment study for AML.

3. . ECOG performance status greater than 2

4. . Uncontrolled intercurrent illness including, but not limited to: uncontrolled
ongoing infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements.

5. . QT interval corrected for heart rate (QTcB) greater than 480 msec (including
subjects on medication). Subjects with a ventricular pacemaker for whom QT interval
is not measurable may be eligible for enrollment after consultation with the drug
manufacturer and study Medical Monitor, and written documentation of this approval.

6. . Female subjects who are pregnant or breastfeeding